Research progress and coping strategy of the drug resistant mechanism of platinum anti-tumor drugs
10.12206/j.issn.1006-0111.202204046
- VernacularTitle:铂类抗肿瘤药物耐药机制的研究进展和应对策略
- Author:
Dongbo WANG
1
;
Jing NIE
1
;
Huina WU
1
;
Lei SUN
1
;
Lihui LIU
1
;
Jiyong WU
1
Author Information
1. Department of Pharmacy, Shandong Second Provincial General Hospital, Jinan 250022, China.
- Keywords:
platinum drugs;
anti-tumor drugs;
drug resistance mechanism
- From:
Journal of Pharmaceutical Practice
2022;40(4):302-308
- CountryChina
- Language:Chinese
-
Abstract:
Platinum anti-tumor drugs are currently the most widely used first-line chemotherapeutic drugs in clinical practice, and their curative effects are remarkable. However, the problems of platinum drug resistance in non-small cell lung cancer, breast cancer, ovarian cancer and others seriously limit effectiveness and clinical application of platinum drugs. The occurrence of platinum drug resistance is caused by many factors. At present, the resistance mechanism of platinum drugs mainly includes the following aspects: decreasing the accumulation of platinum in cells, increasing the inactivation of platinum in cells, repairing DNA damage and tumor cell apoptosis inactivation. This article reviews the drug resistance mechanism and coping strategy of platinum anti-tumor drugs, providing ideas for the development of platinum anti-tumor drugs and references for overcoming clinical platinum drug resistance.
